Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MDGL Stock Forecast

Madrigal Pharmaceuticals stock forecast is as follows: an average price target of $315.75 (represents a -0.41% downside from MDGL’s last price of $317.04) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

MDGL Price Target

The average price target for Madrigal Pharmaceuticals (MDGL) is $315.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $410.00 to $111.00. This represents a potential -0.41% downside from MDGL's last price of $317.04.

MDGL Analyst Ratings

Buy

According to 12 Wall Street analysts, Madrigal Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MDGL stock is 0 'Strong Buy' (0.00%), 9 'Buy' (75.00%), 3 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Madrigal Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 29, 2024	Yasmeen Rahimi	Piper Sandler	$336.00	$221.75	51.52%	5.98%
May 09, 2024	Ed Acre	H.C. Wainwright	$390.00	$208.04	87.46%	23.01%
Mar 19, 2024	Liisa Bayko	Evercore ISI	$405.00	$265.68	52.44%	27.74%
Mar 15, 2024	Eliana Merle	UBS	$410.00	$270.37	51.64%	29.32%
Mar 15, 2024	Akash Tewari	Jefferies	$400.00	$270.37	47.95%	26.17%
Mar 15, 2024	Ed Acre	H.C. Wainwright	$425.00	$270.37	57.19%	34.05%
Mar 15, 2024	Jonathan Wolleben	JMP Securities	$397.00	$270.37	46.84%	25.22%
Mar 15, 2024	Mayank Mamtani	B.Riley Financial	$270.00	$270.37	-0.14%	-14.84%
Jan 05, 2023	-	JMP Securities	$390.00	$274.48	42.09%	23.01%
Dec 21, 2022	-	UBS	$337.00	$257.12	31.07%	6.30%

Row per page

Go to

The latest Madrigal Pharmaceuticals stock forecast, released on May 29, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $336.00, which represents a 51.52% increase from the stock price at the time of the forecast ($221.75), and a 5.98% increase from MDGL last price ($317.04).

Madrigal Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	8
Avg Price Target	-	-	$379.13
Last Closing Price	$317.04	$317.04	$317.04
Upside/Downside	-100.00%	-100.00%	19.58%

In the current month, the average price target of Madrigal Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Madrigal Pharmaceuticals's last price of $317.04. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 16, 2024	JMP Securities	Outperform	Outperform	Hold
Jun 28, 2024	Cantor Fitzgerald	-	Neutral	Initialise
Jun 10, 2024	Wolfe Research	-	Outperform	Initialise
Jun 06, 2024	Citigroup	Buy	Buy	Hold
May 29, 2024	Piper Sandler	Overweight	Overweight	Hold
May 10, 2024	B. Riley	Neutral	Neutral	Hold
May 09, 2024	H.C. Wainwright	Buy	Buy	Hold
Apr 22, 2024	Bank of America Securities	-	Underperform	Initialise
Dec 21, 2022	UBS	Buy	Buy	Hold
Dec 20, 2022	Oppenheimer	Buy	Buy	Hold

Row per page

Go to

Madrigal Pharmaceuticals's last stock rating was published by JMP Securities on Jul 16, 2024. The company gave MDGL a "Outperform" rating, the same as its previous rate.

Madrigal Pharmaceuticals Financial Forecast

Madrigal Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 19	Mar 17	Mar 16	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$147.00K	$1.14M	$4.02M	$4.51M	-
Avg Forecast	$431.20M	$216.05M	$166.19M	$132.95M	$153.35M	$133.33M	$117.67M	$97.42M	$87.37M	$34.60M	$4.25M	$114.77K	$5.69M	$2.95M	$1.82M	$5.45M	$3.46M	$91.32K	$1.13M	$3.50M	$3.50M	$1.29M
High Forecast	$515.20M	$258.14M	$198.57M	$158.85M	$183.22M	$159.31M	$140.60M	$118.16M	$101.28M	$41.34M	$4.25M	$114.88K	$6.82M	$3.54M	$2.19M	$6.54M	$4.15M	$109.59K	$1.36M	$4.20M	$4.20M	$1.55M
Low Forecast	$305.70M	$153.17M	$117.82M	$94.26M	$108.71M	$94.53M	$83.42M	$69.50M	$48.77M	$24.53M	$4.25M	$114.65K	$4.55M	$2.36M	$1.46M	$4.36M	$2.77M	$73.06K	$907.00K	$2.80M	$2.80M	$1.03M
# Analysts	3	3	3	3	4	4	4	6	10	9	9	9	12	8	10	17	12	20	13	14	8	13
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.61%	1.01%	1.15%	1.29%	-

Madrigal Pharmaceuticals's average Quarter revenue forecast for Mar 13 based on 12 analysts is $3.46M, with a low forecast of $2.77M, and a high forecast of $4.15M. MDGL's average Quarter revenue forecast represents a 2251.67% increase compared to the company's last Quarter revenue of $147.00K (Mar 12).

Madrigal Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 19	Mar 17	Mar 16	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08
# Analysts	3	3	3	3	4	4	4	6	10	9	9	9	12	8	10	17	12	20	13	14	8	13
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-15.05M	$-6.00M	$-6.40M	$-22.74M	$-20.16M	$-14.82M	$-10.53M	$-8.79M	$-22.71M	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-17.90M	$-7.70M	$-12.80M	$-23.26M	$-17.70M	$-13.41M	$-10.84M	$-7.54M	$-16.21M	$-16.89M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-14.32M	$-6.16M	$-10.24M	$-18.61M	$-14.16M	$-10.73M	$-8.67M	$-6.03M	$-12.97M	$-13.51M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$-21.49M	$-9.23M	$-15.36M	$-27.91M	$-21.24M	$-16.10M	$-13.01M	$-9.04M	$-19.46M	$-20.27M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.84%	0.78%	0.50%	0.98%	1.14%	1.10%	0.97%	1.17%	1.40%	-

undefined analysts predict MDGL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Madrigal Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Madrigal Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 19	Mar 17	Mar 16	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08
# Analysts	3	3	3	3	4	4	4	6	10	9	9	9	12	8	10	17	12	20	13	14	8	13
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-15.08M	$-6.00M	$-6.52M	$-23.56M	$-20.73M	$-15.05M	$-11.40M	$-9.31M	$-23.50M	-
Avg Forecast	$163.96M	$-13.92M	$-45.88M	$-67.19M	$-50.63M	$-62.42M	$-72.27M	$-83.31M	$-100.22M	$-146.74M	$-163.89M	$-136.67M	$-14.92M	$-7.70M	$-13.05M	$-24.10M	$-18.20M	$-13.62M	$-11.74M	$-7.98M	$-16.78M	$-17.56M
High Forecast	$205.49M	$-8.65M	$-28.52M	$-41.77M	$-31.47M	$-38.80M	$-44.93M	$-67.04M	$-83.19M	$-91.22M	$-101.88M	$-84.96M	$-11.94M	$-6.16M	$-10.44M	$-19.28M	$-14.56M	$-10.90M	$-9.39M	$-6.38M	$-13.42M	$-14.05M
Low Forecast	$101.92M	$-17.44M	$-57.50M	$-84.21M	$-63.45M	$-78.23M	$-90.57M	$-100.24M	$-134.06M	$-183.91M	$-205.39M	$-171.29M	$-17.91M	$-9.23M	$-15.66M	$-28.92M	$-21.84M	$-16.35M	$-14.09M	$-9.57M	$-20.14M	$-21.07M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	0.78%	0.50%	0.98%	1.14%	1.10%	0.97%	1.17%	1.40%	-

Madrigal Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MDGL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Madrigal Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 19	Mar 17	Mar 16	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08
# Analysts	3	3	3	3	4	4	4	6	10	9	9	9	12	8	10	17	12	20	13	14	8	13
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$5.75M	$1.70M	$3.04M	$5.32M	$3.88M	$2.65M	$2.67M	$3.09M	$4.07M	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$5.69M	$2.17M	-	$5.45M	$3.41M	-	-	$2.65M	$2.91M	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$6.82M	$2.61M	-	$6.54M	$4.09M	-	-	$3.17M	$3.49M	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	$4.55M	$1.74M	-	$4.36M	$2.72M	-	-	$2.12M	$2.32M	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	0.78%	-	0.98%	1.14%	-	-	1.17%	1.40%	-

Madrigal Pharmaceuticals's average Quarter SG&A projection for Mar 24 is -, based on 9 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to MDGL last annual SG&A of $5.75M (Mar 19).

Madrigal Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 19	Mar 17	Mar 16	Mar 14	Mar 13	Mar 12	Mar 11	Mar 10	Mar 09	Mar 08
# Analysts	3	3	3	3	4	4	4	6	10	9	9	9	12	8	10	17	12	20	13	14	8	13
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.98	$-0.50	$-1.75	$-9.80	$-10.50	$-9.45	$-9.45	$-8.40	$-24.15	-
Avg Forecast	$7.54	$-0.64	$-2.11	$-3.09	$-2.33	$-2.87	$-3.32	$-3.83	$-4.61	$-6.75	$-7.54	$-6.29	$-1.00	$-1.12	$-2.10	$-10.26	$-8.22	$-7.81	$-10.03	$-6.30	$-13.41	$-18.02
High Forecast	$9.45	$-0.40	$-1.31	$-1.92	$-1.45	$-1.78	$-2.07	$-3.08	$-3.83	$-4.19	$-4.68	$-3.91	$-1.00	$-0.89	$-1.68	$-8.21	$-6.58	$-6.25	$-8.02	$-5.04	$-10.73	$-14.42
Low Forecast	$4.69	$-0.80	$-2.64	$-3.87	$-2.92	$-3.60	$-4.17	$-4.61	$-6.16	$-8.46	$-9.45	$-7.88	$-1.00	$-1.34	$-2.52	$-12.31	$-9.86	$-9.37	$-12.04	$-7.56	$-16.09	$-21.62
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.98%	0.45%	0.83%	0.96%	1.28%	1.21%	0.94%	1.33%	1.80%	-

According to undefined Wall Street analysts, Madrigal Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MDGL previous annual EPS of $NaN (undefined).

Madrigal Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
XFOR	X4 Pharmaceuticals	$0.34	$3.67	979.41%	Buy
INZY	Inozyme Pharma	$2.79	$14.67	425.81%	Buy
PLRX	Pliant Therapeutics	$12.73	$39.71	211.94%	Buy
ABOS	Acumen Pharmaceuticals	$2.37	$7.00	195.36%	Buy
DAWN	Day One Biopharmaceuticals	$13.62	$38.80	184.88%	Buy
ETNB	89bio	$7.98	$22.00	175.69%	Buy
STOK	Stoke Therapeutics	$11.31	$30.60	170.56%	Buy
IOVA	Iovance Biotherapeutics	$8.14	$21.00	157.99%	Buy
TERN	Terns Pharmaceuticals	$5.60	$14.25	154.46%	Buy
VKTX	Viking Therapeutics	$51.53	$102.40	98.72%	Buy
MREO	Mereo BioPharma Group	$3.58	$6.75	88.55%	Buy
SRPT	Sarepta Therapeutics	$110.86	$169.06	52.50%	Buy
PTCT	PTC Therapeutics	$41.96	$46.50	10.82%	Hold
KRYS	Krystal Biotech	$178.10	$191.00	7.24%	Buy
MDGL	Madrigal Pharmaceuticals	$317.09	$315.75	-0.42%	Buy
ACLX	Arcellx	$87.22	$83.00	-4.84%	Buy
TGTX	TG Therapeutics	$31.15	$27.60	-11.40%	Buy

MDGL Forecast FAQ

Is Madrigal Pharmaceuticals a good buy?

Yes, according to 12 Wall Street analysts, Madrigal Pharmaceuticals (MDGL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 75.00% of MDGL's total ratings.

What is MDGL's price target?

Madrigal Pharmaceuticals (MDGL) average price target is $315.75 with a range of $111 to $410, implying a -0.41% from its last price of $317.04. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Madrigal Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for MDGL stock, the company can go down by -0.41% (from the last price of $317.04 to the average price target of $315.75), up by 29.32% based on the highest stock price target, and down by -64.99% based on the lowest stock price target.

Can Madrigal Pharmaceuticals stock reach $500?

MDGL's average twelve months analyst stock price target of $315.75 does not support the claim that Madrigal Pharmaceuticals can reach $500 in the near future.

What are Madrigal Pharmaceuticals's analysts' financial forecasts?

Madrigal Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $501.78M (high $601.28M, low $356.17M), average EBITDA is $0 (high $0, low $0), average net income is $-269M (high $-182M, low $-332M), average SG&A $0 (high $0, low $0), and average EPS is $-12.353 (high $-8.38, low $-15.29). MDGL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $946.4M (high $1.13B, low $670.94M), average EBITDA is $0 (high $0, low $0), average net income is $36.97M (high $126.54M, low $-57.235M), average SG&A $0 (high $0, low $0), and average EPS is $1.7 (high $5.82, low $-2.632).

Did the MDGL's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Mar 2012), Madrigal Pharmaceuticals's revenue was $147K, beating the average analysts' forecast of $91.32K by 60.97%. The company's EBITDA was $-14.821M, beating the average prediction of $-13.413M by 10.50%. Madrigal Pharmaceuticals's net income was $-15.051M, beating the average estimation of $-13.621M by 10.50%. The company's SG&A was $2.65M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-9.45, beating the average prediction of $-7.81 by 21.00%